Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis

Abstract Context Risk of cancer is a major concern in the development of drugs for the treatment of obesity and diabetes. In randomized controlled trials (RCTs) of the Liraglutide Clinical Development Program, subjects treated with a glucagon-like peptide-1 receptor agonist (GLP-1RA) had a higher ab...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of clinical endocrinology and metabolism 2021-03, Vol.106 (3), p.912-921
Hauptverfasser:	Piccoli, Giovana F, Mesquita, Leonardo A, Stein, Cinara, Aziz, Marina, Zoldan, Maira, Degobi, Nathália A H, Spiazzi, Bernardo F, Lopes Junior, Gilberto L, Colpani, Verônica, Gerchman, Fernando
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonists Breast cancer Care and treatment Clinical trials Development and progression Diabetes Diabetes mellitus Diabetes therapy Drug development GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Health aspects Liraglutide Medical research Medicine, Experimental Meta-analysis Obesity Risk factors Tumors Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!